14th September 2015  Content supplied by: Nanosphere, Inc.

Labs Only Pay for Targets Ordered on Respiratory Pathogen Panel


Now with FDA 510(k) clearance Nanosphere's Verigene® Respiratory Pathogens Flex Test (RP Flex) is an automated, multiplex, and flexible nucleic acid test for the identification of the viruses and bacteria that most commonly cause respiratory infections.

The first test of its kind, RP Flex features Nanosphere’s novel Flex™ software, which allows the 16 viral and bacterial targets identified by RP Flex to be reported as a full multiplex panel or in various user-defined subsets. Labs pay for only the targets ordered for each patient sample.

Additional target results not originally reported can be revealed instantly without running an additional test if the clinician requests additional testing for a given patient. With this built-in flexibility, RP Flex can provide labs with a solution for flu only testing, flu and RSV testing, broad respiratory viral testing, and pertussis-only testing all from a single cartridge.

“The demand and need for respiratory pathogen testing varies by season, geography, epidemiology and patient demographics,” said Paul Granato, Ph.D., Director of Microbiology at Laboratory Alliance of Central New York and Professor Emeritus of Pathology at SUNY Upstate Medical University. “RP Flex is the first respiratory test that provides labs with the flexibility to choose and pay for only the microbial targets applicable to a given patient, which in turn allows them to practice better test stewardship and reduce healthcare costs.”

Click here to learn more about RP Flex


    

Tags:

Date Published: 14th September 2015

Source article link: View


View full company details


Related news